Clinical Study
Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients
Table 2
Laboratory values prior to treatment.
| | Parameters | All () | Responders () | Nonresponders () | value |
| | Hematocrit—% | 27 (20–38) | 27 (20–38) | 27 (24–38) | 0.77 | | WBC (/L) | 12 (2.0–35) | 12 (2.0–16) | 12 (6.2–35) | 0.60 | | Potassium—mmol/L | 4.9 (4.0–5.2) | 4.7 (4.3–5.2) | 4.9 (4.0–5.1) | 0.55 | | Magnesium—mmol/L | 0.94 (0.77–2.3) | 0.91 (0.77–1.6) | 1.03 (0.88–2.3) | 0.03 | | C-reactive protein—mg/L | 123 (2–312) | 122 (2–312) | 124 (30–309) | 0.79 | | Procalcitonin—ng/L | 1.1 (0.30–29) | 1.4 (0.50–29) | 0.97 (0.30–17) | 0.63 | | Creatine kinase—U/L | 269 (11–762) | 279 (11–762) | 204 (39–567) | 0.88 | | Troponin—ug/L | 0.40 (0.04–4.8) | 0.37 (0.04–4.8) | 0.41 (0.07–1.5) | 0.75 | | Creatinine—umol/L | 92 (48–535) | 92 (48–535) | 92 (55–534) | 0.88 | | Urea—mmol/L | 11 (3.4–25) | 8.8 (4.8–16) | 11 (3.4–25) | 0.18 | | Base excess | −0.55 (−6.6–+6.3 | −0.55 (−2.7–+6.3) | −0.35 (−6.6–+1.5) | 0.42 | | Bicarbonate—mmol/L | 24 (20–30) | 24 (22–30) | 25 (20–26) | 0.56 |
|
|
WBC: white blood cell count. Results are given as median (minimum–maximum). Groups were compared with the Mann-Whitney test.
|
